Oct 19, 2017 (Marketwired via COMTEX) -- ViaDerma's Manufacturer has completed the first run of its topical antibiotic being sold as VitaStem by its Sales, Marketing and Distribution Partner Biogenx, Inc.; Distribution will begin as the product is shipped to Distribution points in Florida and Abroad LOS ANGELES, CA--(Marketwired - October 19, 2017) - ViaDerma, Inc. (otc pink:VDRM), a specialty pharmaceutical company devoted to bringing new products to market, recently announced today that the Company has begun distribution of its highly anticipated topical antibiotic ointment. Its marketing, sales and distribution partner, Biogenx, Inc. has been preselling the product, under the name of VitaStem™, which retails for $99 and can be purchased online at www.Biogenx.net. The Company's manufacturing partner has completed the first production run of 15,000 units of the product overcoming several manufacturing delays. The Company expects to ramp up production on a monthly basis and the first orders shipped out yesterday. Since the promising results of clinical studies of VitaStem in hospital groups in Japan and the Philippines, the Company will send a portion of the first run to Japan and the Philippines. The Distributors are also interested in ViaDerma's several follow-on products, using ViaDerma's proprietary solution, which the Company is expecting additional FDA registration numbers throughout the rest of 2017. $VDRM